Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis.

Alajbegovic S, Sanders JW, Atherly DE, Riddle MS.

Syst Rev. 2012 Aug 28;1:39. doi: 10.1186/2046-4053-1-39. Review.

2.

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.

DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F.

Ann Intern Med. 2005 May 17;142(10):805-12. Erratum in: Ann Intern Med. 2005 Aug 2;143(3):239.

PMID:
15897530
3.

Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Hu Y, Ren J, Zhan M, Li W, Dai H.

J Travel Med. 2012 Dec;19(6):352-6. doi: 10.1111/j.1708-8305.2012.00650.x. Epub 2012 Sep 14.

4.

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.

Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL.

J Travel Med. 2010 Mar-Apr;17(2):111-7. doi: 10.1111/j.1708-8305.2009.00385.x.

5.

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

Menees SB, Maneerattannaporn M, Kim HM, Chey WD.

Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1. Review.

PMID:
22045120
6.

Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.

DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F.

Clin Infect Dis. 2005 Dec 1;41 Suppl 8:S571-6.

7.

A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey.

Armstrong AW, Ulukan S, Weiner M, Mostafa M, Shaheen H, Nakhla I, Tribble DR, Riddle MS.

J Travel Med. 2010 Nov-Dec;17(6):392-4. doi: 10.1111/j.1708-8305.2010.00462.x.

8.

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Koo HL, DuPont HL.

Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. Review.

9.

A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season.

Flores J, Dupont HL, Jiang ZD, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I, Paredes M.

J Travel Med. 2011 Sep-Oct;18(5):333-6. doi: 10.1111/j.1708-8305.2011.00549.x. Epub 2011 Aug 1.

10.

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.

Infante RM, Ericsson CD, Jiang ZD, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL.

Clin Gastroenterol Hepatol. 2004 Feb;2(2):135-8.

PMID:
15017618
11.

Therapy of travelers' diarrhea with rifaximin on various continents.

Steffen R, Sack DA, Riopel L, Jiang ZD, Stürchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL.

Am J Gastroenterol. 2003 May;98(5):1073-8.

PMID:
12809830
12.

Travelers' preferences for the treatment and prevention of acute diarrhea.

Ericsson CD, Melgarejo NA, Jelinek T, McCarthy A; International Society of Travel Medicine Clinical Research Group.

J Travel Med. 2009 May-Jun;16(3):172-8. doi: 10.1111/j.1708-8305.2009.00317.x. Epub 2009 May 5. Erratum in: J Travel Med. 2010 May-Jun;17(3):181.

13.

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.

Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, Dupont HL.

Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.

14.

Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.

Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F.

Clin Gastroenterol Hepatol. 2007 Apr;5(4):451-6. Epub 2007 Mar 26.

PMID:
17382603
15.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
16.

Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.

Zanger P, Nurjadi D, Gabor J, Gaile M, Kremsner PG.

Lancet Infect Dis. 2013 Nov;13(11):946-54. doi: 10.1016/S1473-3099(13)70221-4. Epub 2013 Sep 4.

PMID:
24012319
17.

Travelers' diarrhea: antimicrobial therapy and chemoprevention.

DuPont HL.

Nat Clin Pract Gastroenterol Hepatol. 2005 Apr;2(4):191-8; quiz 1 p following 198. Review.

PMID:
16265184
18.

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.

DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, Jiang ZD, Mosavi A, de la Cabada FJ.

Digestion. 1998 Nov-Dec;59(6):708-14.

PMID:
9813398
19.

Rifaximin (Xifaxan) for travelers' diarrhea.

[No authors listed]

Med Lett Drugs Ther. 2004 Sep 13;46(1191):74-5. No abstract available.

PMID:
15365508
20.

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.

Gerard L, Garey KW, DuPont HL.

Expert Rev Anti Infect Ther. 2005 Apr;3(2):201-11. Review.

PMID:
15918778
Items per page

Supplemental Content

Write to the Help Desk